Ampyra (dalfampridine) is protected by exclusivity rights that prohibit a generic version of the drug from being manufactured. However, the exclusivity rights are set to expire in 2017, which is the earliest predictable date that a generic version may be available. Dalfampridine is the active ingredient in Ampyra, but it is not a generic version of the drug.
Can I Buy Generic Ampyra?Ampyra™ (dalfampridine) is a medication prescribed to improve walking in people with multiple sclerosis (MS). More specifically, Ampyra helps to increase walking speed.
Ampyra is made by Acorda Therapeutics, Inc. Ampyra is protected from generic competition by exclusivity rights that have not yet expired.
When Will a Generic Version Be Available?
Acorda Therapeutics holds the exclusive rights to market Ampyra in the United States until January 2017. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Ampyra uses. Once the drug goes off patent, there may be several companies that manufacture a generic Ampyra drug.
Is Dalfampridine, 4-Aminopyridine, or Fampridine a Generic Ampyra?No -- dalfampridine is the active ingredient in Ampyra, but it is not a generic version of it. 4-aminopyridine (4-AP) and fampridine are other names for dalfampridine that are commonly used by compounding pharmacists.
There are no commercially available generic versions of Ampyra. Compounded 4-aminopyridine or fampridine medications (made directly in a pharmacy) cannot be considered generic versions, either.